Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5402MR)

This product GTTS-WQ5402MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5402MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ1498MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ10183MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13343MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ2228MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ5079MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ12116MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ15858MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW